J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea
· Delayed Price · Currency is KRW 7,350.00
-400.00 (-5.16%)
At close: Mar 9, 2026
J2KBIO Revenue
J2KBIO had revenue of 8.56B KRW in the quarter ending September 30, 2025, with 31.49% growth. This brings the company's revenue in the last twelve months to 31.12B, down -10.32% year-over-year. In the year 2024, J2KBIO had annual revenue of 33.13B with 16.36% growth.
Revenue (ttm)
31.12B
Revenue Growth
-10.32%
P/S Ratio
1.38
Revenue / Employee
576.38M
Employees
54
Market Cap
42.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.13B | 4.66B | 16.36% |
| Dec 31, 2023 | 28.47B | 12.44B | 77.60% |
| Dec 31, 2022 | 16.03B | 1.81B | 12.75% |
| Dec 31, 2021 | 14.22B | 360.95M | 2.60% |
| Dec 31, 2020 | 13.86B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NGeneBio | 9.98B |
| SCM Lifescience | 1.54B |
| EyeGene | 4.10B |
| Aptamer Sciences | 1.08B |
| Kainos Medicine | 938.87M |
| Eutilex.Co.,Ltd | 10.54B |
| Epibiotech | 449.62M |
| SunBio,Inc. | 2.17B |